Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...
Thermo Fisher is closing a factory in Lexington, MA, and merging operations with a newer facility in Plainville, MA, to ...
The FDA has removed a clinical hold on Novavax’s flu-Covid combination shot and standalone flu vaccine, less than a month ...
Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical ...
Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of ...
The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to ...
Assertio Holdings responded to activist investor Alexander Parker after Parker's firm accused Assertio of fraud. The Buxton Helmsley Group on Friday released an open letter to Assertio’s stockholders, ...
The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech ...
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...
The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback